Literature DB >> 3705923

Cognitive performance in early Parkinson's disease.

M Hietanen, H Teräväinen.   

Abstract

The cognitive, memory and psychomotor performance of 67 patients with Parkinson's disease who had not received any antiparkinson medication was compared with the performance of 43 healthy subjects matched by age and education. The principal impairments in the patients were motor ones, evident in various tests such as general motor slowness and delayed initiation of movement, and they correlated with clinical rigidity and hypokinesia but not with tremor. The performance of the patients was inferior to that of the controls in memory tests involving the processing of information and learning (logical memory, associative learning) but not in less demanding tasks such as the retrieval of numbers. The total disability was due to a combined effect of aging and disease. A decrease of about 15% in the psychomotor and cognitive performance, related to aging alone, can be expected to occur between the ages of 50 and 70. The performance of the patients in memory tests and other tests evaluating cognitive capacity did not correlate either with their motor disability or with their mood. A possibility therefore exists that biological processes behind the cognitive decline and the motor disability are separate, even if they may occur simultaneously.

Entities:  

Mesh:

Year:  1986        PMID: 3705923     DOI: 10.1111/j.1600-0404.1986.tb03257.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  11 in total

1.  Bimanual simultaneous motor performance and impaired ability to shift attention in Parkinson's disease.

Authors:  M W Horstink; H J Berger; K P van Spaendonck; J H van den Bercken; A R Cools
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

2.  Behavioral toxicology of cognition: extrapolation from experimental animal models to humans: behavioral toxicology symposium overview.

Authors:  Merle G Paule; Leonard Green; Joel Myerson; Maria Alvarado; Jocelyne Bachevalier; Jay S Schneider; Susan L Schantz
Journal:  Neurotoxicol Teratol       Date:  2012-01-28       Impact factor: 3.763

3.  Cognitive functioning after pallidotomy for refractory Parkinson's disease.

Authors:  K Perrine; M Dogali; E Fazzini; D Sterio; E Kolodny; D Eidelberg; O Devinsky; A Beric
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

Review 4.  Neuropsychological aspects of Parkinson's disease.

Authors:  S A Raskin; J C Borod; J Tweedy
Journal:  Neuropsychol Rev       Date:  1990-09       Impact factor: 7.444

5.  Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Authors:  Jay S Schneider; Jordan J Elm; Sotirios A Parashos; Bernard M Ravina; Wendy R Galpern
Journal:  Parkinsonism Relat Disord       Date:  2010-07-02       Impact factor: 4.891

Review 6.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

7.  Planning and spatial working memory in Parkinson's disease.

Authors:  R G Morris; J J Downes; B J Sahakian; J L Evenden; A Heald; T W Robbins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

8.  The effect of age of disease onset on neuropsychological performance in Parkinson's disease.

Authors:  M Hietanen; H Teräväinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-02       Impact factor: 10.154

9.  Levodopa and the feedback process on set-shifting in Parkinson's disease.

Authors:  Wing Lok Au; Juan Zhou; Paulito Palmes; Yih-Yian Sitoh; Louis Cs Tan; Jagath C Rajapakse
Journal:  Hum Brain Mapp       Date:  2011-03-24       Impact factor: 5.038

10.  Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Lacey Pflibsen; Katherine A Stang; Michelle D Sconce; Vanessa B Wilson; Rebecca L Hood; Charles K Meshul; Suzanne H Mitchell
Journal:  J Neurosci Res       Date:  2015-08-31       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.